As another example, the detection of specific chromosome aberrations, such as t(9;22)(q34;q11.2) for BCR-ABL1, which results in the formation of the Philadelphia (Ph) chromosome, or t(12;21) aberrations of TEL/AML1 gene translocations are used to assign B-ALL patients to specific targeted therapies [67]. This evidence concerns the gene ETV6 and acute lymphoblastic leukemia.